Venus Remedies Limited (VENUSREM) - Total Liabilities
Based on the latest financial reports, Venus Remedies Limited (VENUSREM) has total liabilities worth Rs1.74 Billion INR (≈ $18.79 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore VENUSREM long-term investments to assets to see how much of total assets are deployed in long-term investments.
Venus Remedies Limited - Total Liabilities Trend (2006–2025)
This chart illustrates how Venus Remedies Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Venus Remedies Limited total assets.
Venus Remedies Limited Competitors by Total Liabilities
The table below lists competitors of Venus Remedies Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Natures Sunshine Products Inc
NASDAQ:NATR
|
USA | $90.51 Million |
|
Advanced Information Technology Public Company Limited
BK:AIT
|
Thailand | ฿2.60 Billion |
|
Torrid Holdings Inc
NYSE:CURV
|
USA | $614.44 Million |
|
Ard Grup Bilisim Teknolojileri AS
IS:ARDYZ
|
Turkey | TL2.11 Billion |
|
Hocheng Corp
TW:1810
|
Taiwan | NT$2.17 Billion |
|
Stellus Capital Investment
NYSE:SCM
|
USA | $638.28 Million |
|
AC IMMUNE SA SF-02
F:IMR
|
Germany | €115.23 Million |
|
Cint Group AB
ST:CINT
|
Sweden | Skr145.95 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Venus Remedies Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Venus Remedies Limited (VENUSREM) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.15 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Venus Remedies Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Venus Remedies Limited (2006–2025)
The table below shows the annual total liabilities of Venus Remedies Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs1.55 Billion ≈ $16.74 Million |
+11.13% |
| 2024-03-31 | Rs1.39 Billion ≈ $15.06 Million |
-1.04% |
| 2023-03-31 | Rs1.41 Billion ≈ $15.22 Million |
+0.98% |
| 2022-03-31 | Rs1.39 Billion ≈ $15.07 Million |
-10.41% |
| 2021-03-31 | Rs1.56 Billion ≈ $16.82 Million |
-50.51% |
| 2020-03-31 | Rs3.14 Billion ≈ $34.00 Million |
-21.47% |
| 2019-03-31 | Rs4.00 Billion ≈ $43.29 Million |
+2.92% |
| 2018-03-31 | Rs3.89 Billion ≈ $42.06 Million |
+3.03% |
| 2017-03-31 | Rs3.78 Billion ≈ $40.83 Million |
-6.83% |
| 2016-03-31 | Rs4.05 Billion ≈ $43.82 Million |
+5.42% |
| 2015-03-31 | Rs3.84 Billion ≈ $41.57 Million |
+3.12% |
| 2014-03-31 | Rs3.73 Billion ≈ $40.31 Million |
+10.14% |
| 2013-03-31 | Rs3.38 Billion ≈ $36.60 Million |
+26.88% |
| 2012-03-31 | Rs2.67 Billion ≈ $28.85 Million |
+19.11% |
| 2011-03-31 | Rs2.24 Billion ≈ $24.22 Million |
+25.17% |
| 2010-03-31 | Rs1.79 Billion ≈ $19.35 Million |
+13.16% |
| 2009-03-31 | Rs1.58 Billion ≈ $17.10 Million |
+32.74% |
| 2008-03-31 | Rs1.19 Billion ≈ $12.88 Million |
+18.59% |
| 2007-03-31 | Rs1.00 Billion ≈ $10.86 Million |
+231.12% |
| 2006-03-31 | Rs303.32 Million ≈ $3.28 Million |
-- |
About Venus Remedies Limited
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormo… Read more